ARTÍCULO ORIGINAL

Immunophenotypic characteristics of diffuse large b-cell lymphoma and expression of C-MYC protein: single Ecuadorian center experience

Johanna Cevallos, Nelson Montalvo
Laboratorio de Patología, Hospital Metropolitano, Quito, Ecuador

*Autor para correspondencia: Johanna Cevallos Correo electrónico: johannacevallosespinel@gmail.com; jace77_7@hotmail.com

Recibido el 29 de agosto de 2018, aprobado el 26 de febrero de 2019.
Disponible en Internet el 25 de junio de 2019

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) makes up from 25% to 40% of all non-Hodgkin lymphomas (NHL) and is the most common histological subtype worldwide. In Ecuador, DLBCL makes up 49% of all NHL cases, but there have been no studies on the immunophenotypic classification of DLBCL in germinal center (GC) and non-germinal center (NGC) subtypes. This study was conducted to ascertain the immunophenotypic profile of DLBCL in an Ecuadorian hospital.

Methods: A total of 38 DLBCL cases from 2006 to 2015 were compiled from the Pathology Service at Metropolitan Hospital (HM) in Quito, Ecuador. Eleven of these cases failed to meet the inclusion criteria; thus, the final sample consisted of 27 cases. Manual tissue microarrays were constructed, and three immunohistochemical markers (CD10, BCL6, and MUM1) were applied according to the Hans algorithm; in addition, the expression of the c-myc protein expression was also investigated.

Results: The results showed that 77.8% of cases were of the GC subtype, 11.1% were NGC, and 11.1% were unclassifiable according to the Hans algorithm.

Conclusions: The most frequent DLBCL subtype was GC, with 21 cases; and 40.7% of these cases overexpressed c-myc.

PALABRAS CLAVE
Linfoma de Células B Grandes Difuso; Centro germinal; Proteínas Proto-Oncogénicas c-myc; Ecuador

https://doi.org/10.35509/01239015.58
0123-9015/©2019 Publicado por Instituto Nacional de Cancerología
**Métodos:** Se recopiló del Servicio de Patología del Hospital Metropolitano de Quito, Ecuador, un total de 38 casos de LDCGB desde el 2006 al 2015, de los cuales 11 no cumplieron con los criterios de inclusión. La muestra final fue de 27 casos. Se realizaron microarreglos tisulares manuales para la aplicación de tres marcadores de inmunohistoquímica según el algoritmo de Hans (CD10, BCL6 y MUM1) y luego se correlacionó con la sobreexpresión de la proteína c-MYC.

**Resultados:** El 77.8% de casos fue tipo CG, 11,1% fue NCG y 11,1% fueron inclasificables según Hans.

**Conclusiones:** El subtipo de LDCGB más frecuente fue CG con 21 casos y de estos 40,7% sobreexpresaron c-MYC.

---

**Introduction**

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of neoplasms that have in common certain morphological, immunophenotypic, and genetic characteristics. DLBCL makes up from 25% to 40% of all non-Hodgkin lymphomas (NHL), and is the most common histological subtype worldwide. In Ecuador, it accounted for 49% of all NHL cases from 2006 to 2010.

In 2008, the World Health Organization (WHO) put forward a new DLBCL classification that includes morphological and molecular variants and immunophenotypic subgroups, resulting in two subtypes: germinal center (GC) and non-germinal center (NGC). This division is based on the Hans immunohistochemical algorithm (CD10, BCL6, and MUM1), which has a high reproducibility and concordance (80-96%) with gene expression profiling using DNA microarrays.

The results of scientific studies on the immunophenotypic division of DLBCL have been published in Europe, Asia, Latin America (Colombia, Brazil, and Guatemala), and the United States. Despite its recognized prognostic and therapeutic value, the immunophenotypic profile of DLBCL in Ecuador is unknown. This study is the first immunophenotypic classification of DLBCL and its correlation with the overexpression of c-MYC protein in the Ecuadorian population.

**Materials and Methods**

**Patients:** We compiled all the DLBCL cases between January 2006 and December 2015 (n = 38) at the Pathology Service of the Metropolitan Hospital in Quito, Ecuador. We excluded 11 cases because they contained insufficient histopathological material to perform the required analyses, ending up with a final sample of 27 cases.

**Histopathology:** The selected paraffin blocks were surgical specimens and biopsies processed according to the Service’s protocols. DLBCL cases were selected if the paraffin blocks contained adequate tissue for manual tissue microarray construction. The DLBCL diagnoses were based on the current 2008 WHO criteria for classification of tumors of hematopoietic and lymphoid tissues.

**Manual Tissue Microarrays and Immunohistochemistry:** The best-preserved area with appropriate morphology was selected to construct manual tissue microarrays with a diameter of 0.4 cm. Sections with a thickness of 4μm were cut and then stained with hematoxylin-eosin (H&E); then immunohistochemical techniques for CD10, BCL6, MUM1, and c-MYC (Table 1 and 2).

**Statistical Analysis:** The epidemiological design was descriptive as a whole regarding all the samples from DLBCL-diagnosed patients in whom the frequency of the immunophenotypic subtypes GC and NGC was determined. The qualitative variables were expressed in simple frequencies and percentages, and the quantitative variables were expressed in averages and standard deviation. Moreover, the expression of the c-myc protein expression was also investigated for each immunophenotypic subtype of DLBCL.

**Results**

Table 3 summarizes the patients’ clinical-pathological characteristics. The average age of the 27 patients was 69.9 ± 16.9 years (range: 39 to 106 years); 51.9% of the subjects (n = 14) were female. The average age of the studied women was 70.5 ± 16.8 years; it was 69.2 ± 17.6 years (p > 0.05) for men. The most frequent locations were extra-nodal (n = 10), predominantly the colon and stomach. H&E staining showed that all the cases had a centroblastic morphology. The immunophenotypic...
subtype was established according to Hans algorithm. The GC subtype accounted for 77.8% of cases; 11.1% of cases were NGC and 11.1% were unclassifiable. The GC subtype predominantly overexpressed c-MYC (in 40.7% of cases).

### Discussion

Classification of DLBCL in GC and NGC subtypes has been carried out in a number of studies worldwide. In Latin America (Guatemala, Brazil, and Colombia), very little has been published on this subject. In Ecuador, our results show GC to be the most frequent immunophenotypic subtype of DLBCL (42.9% versus 33.3% NGC). These results are similar to those obtained by Perry in Guatemala, where the GC subtype predominated. In Colombia, Ospina found GC to be the most frequent subtype (n = 61), whereas Castellanos reported an NGC predominance (n = 40). It is worth noting that two studies in Latin American countries with very different population figures—Brazil, with 210,616,910 inhabitants, and Ecuador, with 16,507,400—were countries with very different population figures—Brazil, with 210,616,910 inhabitants, and Ecuador, with 16,507,400—inhabitants, were reported by the GC subtype. These results are analogous to those of Gupta et al. (n = 40), in which 50% of cases overexpressed c-MYC by IHC and 65% were of the GC subtype. They are also similar to the results of the Perry study (n = 106), in which 46% of patients who overexpressed c-MYC were of the GC subtype. Johnson et al. (n = 72) and Kluk M et al. (n = 77) reported overexpression of c-MYC by IHC in 33% and 11.5% of their DLBCL cases, respectively.

This study is the first immunophenotypic classification of DLBCL with the overexpression of c-MYC protein in the Ecuadorian population. The GC subtype accounted for 77.8% of cases; 11.1% of cases were NGC and 11.1% were unclassifiable. The GC subtype predominantly overexpressed c-MYC (in 40.7% of cases).

Currently, overexpression of the c-MYC protein is considered an IPI-independent prognostic factor for both disease-free and overall survival. Patients who overexpress the c-MYC protein have larger tumors, higher chemo-resistance, a worse prognosis, and shorter survival.

It is required to complement the amplification study of the c-MYC gene by fluorescent in situ hybridization (FISH).

### Conflict of interest

The authors state they have no conflicts of interest.

### References


